Cargando…

Type and dose of heparin in Covid‐19: Reply

Detalles Bibliográficos
Autores principales:	Thachil, Jecko, Tang, Ning, Gando, Satoshi, Falanga, Anna, Levi, Marcel, Clark, Cary, Iba, Toshiaki, Cattaneo, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9770813/ https://www.ncbi.nlm.nih.gov/pubmed/32329221 http://dx.doi.org/10.1111/jth.14870

Ejemplares similares

DOACs and “newer” hemophilia therapies in COVID‐19: Reply
por: Thachil, Jecko, et al.
Publicado: (2020)

ISTH interim guidance on recognition and management of coagulopathy in COVID‐19
por: Thachil, Jecko, et al.
Publicado: (2020)

The application of anticoagulant therapy to sepsis
por: Thachil, Jecko, et al.
Publicado: (2017)

Differentiating biochemical from clinical heparin resistance in COVID-19
por: Lisman, Ton, et al.
Publicado: (2020)

Coagulation abnormalities and thrombosis in patients with COVID-19
por: Levi, Marcel, et al.
Publicado: (2020)

The versatile heparin in COVID‐19
por: Thachil, Jecko
Publicado: (2020)

Clinical significance of measuring plasminogen activator inhibitor-1 in sepsis
por: Iba, Toshiaki, et al.
Publicado: (2017)

Proposal of the Definition for COVID-19-Associated Coagulopathy
por: Iba, Toshiaki, et al.
Publicado: (2021)

Hypoxia—An overlooked trigger for thrombosis in COVID‐19 and other critically ill patients
por: Thachil, Jecko
Publicado: (2020)

The unique characteristics of COVID-19 coagulopathy
por: Iba, Toshiaki, et al.
Publicado: (2020)

Heparin – Messias or Verschlimmbesserung?
por: Swan, Dawn, et al.
Publicado: (2021)

The implications of aspirin resistance in renal failure
por: Thachil, Jecko
Publicado: (2008)

The difficult distinction between haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura
por: Thachil, Jecko
Publicado: (2008)

Usefulness of Combining D-Dimers with Thromboelastography
por: Thachil, Jecko
Publicado: (2020)

Nevertheless, the importance of coagulation abnormalities should be emphasized in international sepsis guidelines
por: Iba, Toshiaki, et al.
Publicado: (2022)

Thrombomodulin in disseminated intravascular coagulation and other critical conditions—a multi-faceted anticoagulant protein with therapeutic potential
por: Ito, Takashi, et al.
Publicado: (2019)

New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey
por: Iba, Toshiaki, et al.
Publicado: (2017)

The Comparison of the Protective Effects of α- and β-Antithrombin against Vascular Endothelial Cell Damage Induced by Histone in Vitro
por: Iba, Toshiaki, et al.
Publicado: (2017)

Reply to Rheumatologists’ perspective on coronavirus disease 19: is heparin the dark horse for COVID-19?
por: Ahmed, Sakir, et al.
Publicado: (2020)

Is it hyperfibrinolysis or fibrinolytic shutdown in severe COVID-19?
por: Nielsen, Nathan D., et al.
Publicado: (2022)

Heparin induced thrombocytopenia-type 2
por: Majeed, Tanveer A.
Publicado: (2010)

Re: Heparin-induced thrombocytopenia – Type 2
por: Yagnik, Vipul D.
Publicado: (2011)

Thrombocytopenia caused by low-dose heparin supplementation of parenteral nutrition solution
por: Lee, Eunyoung, et al.
Publicado: (2013)

Revision of the Japanese Association for Acute Medicine (JAAM) disseminated intravascular coagulation (DIC) diagnostic criteria using antithrombin activity
por: Iba, Toshiaki, et al.
Publicado: (2016)

Is polymyxin B-immobilized fiber column ineffective for septic shock? A discussion on the press release for EUPHRATES trial
por: Iba, Toshiaki, et al.
Publicado: (2017)

The wind changed direction and the big river still flows: from EUPHRATES to TIGRIS
por: Iba, Toshiaki, et al.
Publicado: (2019)

Abnormal coagulation tests before kidney biopsies—what next?
por: Thachil, Jecko
Publicado: (2013)

Lessons learnt from COVID‐19 coagulopathy
por: Thachil, Jecko
Publicado: (2021)

Author`s Reply
por: Çimci, Murat, et al.
Publicado: (2020)

Author`s Reply
por: Çimci, Murat, et al.
Publicado: (2020)

Reply to Yan and Muller, “Remdesivir for COVID-19: Why Not Dose Higher?”
por: Juneja, Kavita, et al.
Publicado: (2021)

In Reply
por: Brandi, Giovanni, et al.
Publicado: (2016)

Reply: Two types of fatigue in cancer patients
por: Singer, S, et al.
Publicado: (2012)

Reply to “raised concern”
por: JOHANNING, Eckardt, et al.
Publicado: (2021)

Authors’ Reply
por: Tendas, Andrea, et al.
Publicado: (2011)

Response to 'Reply to Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy'
por: Tang, Ning
Publicado: (2020)

Refractory hyperkalemia related to heparin abuse
por: Bawaskar, Himmatrao S., et al.
Publicado: (2014)

Heparin-induced bullous hemorrhagic dermatosis()
por: Hamdi, Douja, et al.
Publicado: (2022)

COVID-19 coagulopathy: is it disseminated intravascular coagulation?
por: Levi, Marcel, et al.
Publicado: (2020)

Treatment of acute radiation cystitis: reply by the authors
por: Hazewinkel, Menke, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ht9tsp42hnodqd9p2ogb45tq0p